To appoint Dr. Sol J. Barer to serve as a director until Tevas 2029 annual meeting of Shareholders
To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers
To appoint Kesselman & Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Tevas independent registered public accounting firm until Tevas 2027 annual meeting of shareholders